PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.06%
Positive revenue growth while ECL.AX is negative. John Neff might see a notable competitive edge here.
28.92%
Positive gross profit growth while ECL.AX is negative. John Neff would see a clear operational edge over the competitor.
380.62%
Positive EBIT growth while ECL.AX is negative. John Neff might see a substantial edge in operational management.
380.62%
Positive operating income growth while ECL.AX is negative. John Neff might view this as a competitive edge in operations.
1164.40%
Positive net income growth while ECL.AX is negative. John Neff might see a big relative performance advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.99%
Share reduction while ECL.AX is at 0.17%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.42%
OCF growth at 75-90% of ECL.AX's 107.62%. Bill Ackman would demand better working capital management or cost discipline.
-360.42%
Negative FCF growth while ECL.AX is at 114.38%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-74.99%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-42.26%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-3.11%
Negative 3Y CAGR while ECL.AX stands at 13.23%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
145.92%
Positive long-term OCF/share growth while ECL.AX is negative. John Neff would see a structural advantage in sustained cash generation.
26672.25%
Positive OCF/share growth while ECL.AX is negative. John Neff might see a comparative advantage in operational cash viability.
184.38%
Positive 3Y OCF/share CAGR while ECL.AX is negative. John Neff might see a big short-term edge in operational efficiency.
110.42%
Similar net income/share CAGR to ECL.AX's 116.56%. Walter Schloss would see parallel tailwinds or expansions for both firms.
14569.42%
Positive 5Y CAGR while ECL.AX is negative. John Neff might view this as a strong mid-term relative advantage.
10.26%
Positive short-term CAGR while ECL.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
479.91%
Positive short-term equity growth while ECL.AX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.88%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
12.80%
We show growth while ECL.AX is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
35.81%
Positive asset growth while ECL.AX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.76%
BV/share growth above 1.5x ECL.AX's 1.49%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
15122.66%
Debt growth of 15122.66% while ECL.AX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
92.32%
R&D growth of 92.32% while ECL.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-33.57%
We cut SG&A while ECL.AX invests at 0.97%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.